Provider of ultra-sensitive digital immunoassay platforms for biomarker analysis.
Quanterix Corporation, a leading player in the life sciences industry, specializes in the development and commercialization of digital immunoassay platforms that are pivotal in advancing precision health across global markets including North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's innovative product lineup includes the HD-X instrument, an automated platform renowned for its sensitivity in multiplex protein detection, and the SR-X instrument, which integrates Simoa detection technology for diverse applications, including direct detection of nucleic acids.
Established in 2007 and headquartered in Billerica, Massachusetts, Quanterix Corporation also offers the SP-X instrument featuring Simoa planar array technology, tailored for measuring multiplex chemiluminescent immunoassays. Complementing these platforms are a range of assay kits, consumables, and reagents essential for life science research, along with comprehensive contract research services encompassing sample testing, homebrew assay development, and custom solutions.
With a strong focus on neurology, oncology, cardiology, infectious diseases, and inflammation, Quanterix Corporation serves a diverse customer base including academic and governmental research laboratories, pharmaceutical companies, biotechnology firms, and contract research organizations. Its products and services are distributed globally through a combination of direct sales channels, support networks, and partnerships with distributors and sales agents.
Quanterix Corporation, formerly known as Digital Genomics, Inc., has evolved into a key player in the life sciences sector by consistently innovating and delivering cutting-edge solutions. The company's commitment to precision and reliability underscores its mission to empower researchers and clinicians with advanced tools that drive breakthroughs in diagnostics, therapy development, and understanding of complex diseases.